

# PRALUENT ENROLLMENT FORM

## PATIENT INFORMATION

Last Name \_\_\_\_\_ First Name \_\_\_\_\_  
 Social Security No \_\_\_\_\_ Date of Birth \_\_\_\_\_  
 Sex  M  F Weight \_\_\_\_\_ Height \_\_\_\_\_ Allergies \_\_\_\_\_  
 Home Phone \_\_\_\_\_ Work/Mobile \_\_\_\_\_  
 Home Address \_\_\_\_\_  
 City \_\_\_\_\_ State \_\_\_\_\_ Zip \_\_\_\_\_

## PATIENT INSURANCE INFORMATION

Primary Medical Insurance \_\_\_\_\_ Medical Insurance Phone \_\_\_\_\_  
 Subscriber Name \_\_\_\_\_  
 Rx Card (PBM) \_\_\_\_\_ Group No \_\_\_\_\_  
 Prescription Card Bin # \_\_\_\_\_ PCN # \_\_\_\_\_

## TREATMENT ARRANGMENTS

•Start Date: \_\_\_\_\_ Ship Meds  Home  Doctor's Office  
 Teaching by:  Home Health  Doctor's Office  Other: \_\_\_\_\_

## CLINICAL INFORMATION

### DIAGNOSIS/ICD-10:

**Hypercholesterolemia**  
 E 78.0 Pure hypercholesterolemia  
 E 78.2 Mixed hyperlipidemia  
 E 78.4 Other hyperlipidemia  
**Clinical ASCVD**  
**Ischemic heart Disease**  
 122. \_\_ Acute myocardial infarction  
 122. \_\_ Subsequent myocardial infarction  
 120.9 Angina pectoris  
 125. \_\_ Chronic ischemic heart disease  
**Other ASCVD-specific code(s)** \_\_\_\_\_

**Cerebrovascular and Peripheral Vascular Disease**  
 163. \_\_ Cerebral infarction  
 165. \_\_ Occlusion and stenosis of cerebral arteries (Extracranial)  
 166. \_\_ Occlusion and stenosis of cerebral arteries (Intracranial)  
 167. \_\_ Other cerebrovascular disease  
 170. \_\_ Atherosclerosis  
 173.9 Peripheral vascular disease  
 \_\_\_\_\_

### PREVIOUS/CURRENT THERAPIES

None  
 atorvastatin \_\_\_\_\_ mg/day  
 ezetimibe \_\_\_\_\_ mg/day  
 ezetimibe /simvastatin \_\_\_\_\_ mg/day  
 rosuvastatin \_\_\_\_\_ mg/day  
 simvastatin \_\_\_\_\_ mg/day

Date: \_\_\_\_\_

### Lab Results:

LDL-C \_\_\_\_\_ mg/ml Date: \_\_\_\_\_

## PRESCRIPTION INFORMATION

Prescription	Strength	Directions	Quantity	Refills
<input type="checkbox"/> PRALUENT™ (Alirocumab)	<input type="checkbox"/> 75 mg/mL Pen <input type="checkbox"/> 75 mg/mL PFS <input type="checkbox"/> 150 mg/mL Pen <input type="checkbox"/> 150 mg/mL PFS	<input type="checkbox"/> Inject 75 mg subcutaneously every two (2) weeks <input type="checkbox"/> Inject 150 mg subcutaneously every two (2) weeks	28 days	

Physician Signature: \_\_\_\_\_  DAW (Dispense as Written) Date: \_\_\_\_\_

Physician Name: \_\_\_\_\_ Phone: \_\_\_\_\_ Fax: \_\_\_\_\_ Office Contact: \_\_\_\_\_

Physician Address: \_\_\_\_\_ NPI: \_\_\_\_\_ DEA: \_\_\_\_\_

**IMPORTANT NOTICE:** This message may contain privileged and confidential information and is intended only for the individual named. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document by mistake. Then destroy this document. Please direct all verification or notification to the above mentioned physician's office.

By signing this document you authorize Southside pharmacy to contact insurance companies for prior authorization purposes.

**FAX TO (855) - 822 - 7838**

Specialty Pharmacy | IV Therapy | Home Health | Medical Equipment | Compounding | Physician's Billing

7700 Main St., Houston, TX 77030 | P: 855-822-7828 | www.ssr.com

**"One SOURCE for ALL your Medical NEEDS"**

